Home » Stocks » Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. (CKPT)

Stock Price: $2.10 USD -0.05 (-2.33%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 115.62M
Revenue (ttm) 1.32M
Net Income (ttm) -21.96M
Shares Out 53.04M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $2.10
Previous Close $2.15
Change ($) -0.05
Change (%) -2.33%
Day's Open -
Day's Range 2.10 - 2.21
Day's Volume 731,635
52-Week Range 1.05 - 3.34

More Stats

Market Cap 115.62M
Enterprise Value 93.70M
Earnings Date (est) Oct 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 53.04M
Float 45.33M
EPS (basic) -0.52
EPS (diluted) -0.49
FCF / Share -0.29
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 896,320
Short Ratio 3.17
Short % of Float 2.25%
Beta 2.09
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 87.66
PB Ratio 9.22
Revenue 1.32M
Operating Income -22.11M
Net Income -21.96M
Free Cash Flow -14.92M
Net Cash 21.92M
Net Cash / Share 0.40
Gross Margin -1,335.63%
Operating Margin -1,675.97%
Profit Margin -1,664.70%
FCF Margin -1,130.86%
ROA -72.89%
ROE -197.97%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$14.33*
(582.38% upside)
Low
8.00
Current: $2.10
High
20.00
Target: 14.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue1.713.511.732.570.59
Revenue Growth-51.28%103.25%-32.88%335.59%-
Gross Profit1.713.511.732.570.59
Operating Income-24.85-36.74-22.78-22.16-13.22
Net Income-24.71-36.37-22.68-22.46-13.89
Shares Outstanding35.3028.5522.6221.549.86
Earnings Per Share-0.70-1.27-1.00-1.04-1.41
Operating Cash Flow-21.37-25.81-15.46-9.95-1.11
Free Cash Flow-21.37-25.81-15.46-9.95-1.11
Cash & Equivalents26.0822.0019.2335.0950.42
Total Debt----2.47
Net Cash / Debt26.0822.0019.2335.0947.95
Assets26.9724.9021.4135.9850.65
Liabilities8.1213.096.373.674.26
Book Value18.8511.8115.0432.3146.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Checkpoint Therapeutics, Inc.
Country United States
Employees 8
CEO James F. Oliviero

Stock Information

Ticker Symbol CKPT
Stock Exchange NASDAQ
Unique Identifier NASDAQ: CKPT
IPO Date June 26, 2017

Description

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.